As of 2025-08-25, the Intrinsic Value of MedTech Acquisition Corp (MTAC) is -1.93 USD. This MTAC valuation is based on the model Peter Lynch Fair Value. With the current market price of 11.34 USD, the upside of MedTech Acquisition Corp is -117.02%.
Based on its market price of 11.34 USD and our intrinsic valuation, MedTech Acquisition Corp (MTAC) is overvalued by 117.02%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -1.93 - -1.93 | -1.93 | -117.02% |
| P/E | 14.50 - 18.22 | 17.01 | 50.0% |
| DDM - Stable | 6.27 - 17.94 | 12.11 | 6.7% |
| DDM - Multi | 6.12 - 13.93 | 8.54 | -24.7% |
| Market Cap (mil) | 83.86 |
| Beta | -0.01 |
| Outstanding shares (mil) | 7.39 |
| Enterprise Value (mil) | 83.72 |
| Market risk premium | 5.00% |
| Cost of Equity | 9.06% |
| Cost of Debt | 5.00% |
| WACC | 8.97% |